We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Dynavax Initiates Proof of Mechanism Trial in Lupus Patients

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dynavax Initiates Proof of Mechanism Trial in Lupus Patients"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Dynavax Technologies Corporation has announced the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients.

Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance.

GSK has an exclusive option to obtain a license to the program following completion of this trial.

The first of two stages of the trial will evaluate ascending doses of DV1179 for safety and tolerability in SLE patients, each of whom will receive eight weekly injections of DV1179.

The second stage of the trial will evaluate DV1179's mechanism of action via inhibition of type 1 interferon by enrolling additional SLE patients in selected dose groups.

DV1179 was previously shown to be well-tolerated in a Phase 1 trial in healthy subjects.

"To begin the evaluation of DV1179 in lupus patients is an important achievement for Dynavax," said Tyler Martin, M.D., President and Chief Medical Officer at Dynavax.

Martin continued, "Excessive production of type 1 interferons is thought to be a critical factor in the pathogenesis of lupus. At the completion of this trial, we will be able to determine if DV1179 can reduce interferon levels in lupus patients."